Response of Human Epidermal Growth Factor Receptor 2-Expressing Prostate Cancer to Trastuzumab Deruxtecan.

Autor: Lap CJ; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, and Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC., Rajendran R; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC., Martin JM; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC., Uppal M; The George Washington University School of Medicine, Washington, DC., Escobar A; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC., Heiraty AM; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC., Estephan F; The George Washington University School of Medicine, Washington, DC., Hahn W; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC., Subrahmanyam R; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC., Nava VE; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, and The George Washington University School of Medicine, Washington, DC., Jain M; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, and The George Washington University School of Medicine, Washington, DC.

Publikováno v: Annals of internal medicine [Ann Intern Med] 2024 Nov 05. Date of Electronic Publication: 2024 Nov 05.

The prevalence and clinical significance of HER2 expression in prostate adenocarcinoma.

Autor: Estephan F; The George Washington University School of Medicine and Health Sciences, Washington, DC, USA; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC, USA., Lap CJ; The George Washington University School of Medicine and Health Sciences, Washington, DC, USA; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC, USA., Banagan J; Institute for Clinical Research, Washington, DC, USA., Antonio M; Institute for Clinical Research, Washington, DC, USA., Liu S; Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, Washington, DC, USA., Diao G; Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, Washington, DC, USA., Rozalen AZ; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC, USA., Rajendran R; Institute for Clinical Research, Washington, DC, USA., Krasnow S; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC, USA., Subrahmanyam R; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC, USA., Nava VE; The George Washington University School of Medicine and Health Sciences, Washington, DC, USA; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC, USA., Jain M; The George Washington University School of Medicine and Health Sciences, Washington, DC, USA; The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, Washington, DC, USA. Electronic address: maneesh.jain@va.gov.

Publikováno v: Annals of diagnostic pathology [Ann Diagn Pathol] 2023 Dec; Vol. 67, pp. 152219. Date of Electronic Publication: 2023 Oct 20.

Combined Ruxolitinib and Venetoclax Treatment in a Patient with a BCR-JAK2 Rearranged Myeloid Neoplasm.

Autor: Lap CJ; The George Washington University Medical Faculty Associates, Washington, DC, USA., Nassereddine S; The George Washington University Medical Faculty Associates, Washington, DC, USA., Liu ML; Washington DC Veterans Affairs Medical Center, Washington, DC, USA., Nava VE; Washington DC Veterans Affairs Medical Center, Washington, DC, USA., Aggarwal A; The George Washington University Medical Faculty Associates, Washington, DC, USA.; Washington DC Veterans Affairs Medical Center, Washington, DC, USA.

Publikováno v: Case reports in hematology [Case Rep Hematol] 2021 Jul 28; Vol. 2021, pp. 2348977. Date of Electronic Publication: 2021 Jul 28 (Print Publication: 2021).

The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.

Autor: Nassereddine S; The George Washington University School of Medicine, Washington, DC, USA.; The George Washington Cancer Center, Washington, DC, USA., Lap CJ; The George Washington Cancer Center, Washington, DC, USA., Haroun F; The George Washington University School of Medicine, Washington, DC, USA., Tabbara I; The George Washington University School of Medicine, Washington, DC, USA. itabbara@mfa.gwu.edu.; The George Washington Cancer Center, Washington, DC, USA. itabbara@mfa.gwu.edu.; Division of Hematology/Oncology and GW Cancer Center, George Washington University Medical Faculty Associates, 2150 Pennsylvania Avenue, NW, Washington, DC, 20037, USA. itabbara@mfa.gwu.edu.

Publikováno v: Annals of hematology [Ann Hematol] 2017 Dec; Vol. 96 (12), pp. 1983-1991. Date of Electronic Publication: 2017 Oct 31.

Chicken HS4 insulators have minimal barrier function among progeny of human hematopoietic cells transduced with an HIV1-based lentiviral vector.

Autor: Uchida N; Molecular and Clinical Hematology Branch, National Heart Lung and Blood Institutes (NHLBI)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), Bethesda, Maryland, USA., Washington KN, Lap CJ, Hsieh MM, Tisdale JF

Publikováno v: Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2011 Jan; Vol. 19 (1), pp. 133-9. Date of Electronic Publication: 2010 Oct 12.